Effect of growth hormone on euploid blastocyst rate in advanced-age women: a prospective, randomized, controlled trial

Older women exhibit an increased incidence of chromosomal abnormalities in preimplantation embryos. At present, it remains uncertain whether growth hormone (GH) administration can improve embryonic ploidy status in this population.This study aimed to investigate whether GH administration can improve the euploid blastocyst rate in older women undergoing preimplantation genetic testing for aneuploidy (PGT-A). This is a prospective, randomized, controlled trial.We included 316 advanced-age infertile women (≥ 35 years) undergoing PGT-A.Participants in the GH group received subcutaneous GH injection at a dose of 2 IU/day starting from the mid-luteal phase of the two menstrual cycles preceding the initiation of ovarian stimulation. Between the initiation of ovarian stimulation and the day of human chorionic gonadotropin (HCG) trigger, GH was administered at an increased dose of 4 IU/day.The control group did not receive additional interventions. The primary endpoint was the euploid blastocyst rate which was calculated as follows: number of euploid blastocysts/total number of blastocysts × 100%. The number of euploid blastocysts per patient was 0.98 ± 0.99 in the GH group and 0.89 ± 0.99 in the control group ( P = 0.534; absolute difference [95% CI]: 0.00 [− 0.00, 0.00]). Further, there was no significant difference in the euploid blastocyst rate between the GH group (37.78% ± 36.77%) and the control group (31.55% ± 33.99%; P = 0.325; absolute difference [95% CI]: 0.01% [-0.00%, 16.67%]). Our findings indicated that GH supplementation did not significantly improve the euploid blastocyst rate in advanced-age women undergoing PGT-A. These findings suggest that routine GH co-treatment may not increase the euploid rate in this population. Trial registration: ChiCTR2100052433; http://www.chictr.org.cn , Oct 26, 2021.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-21
DOI
https://doi.org/10.1038/s41598-026-77929-0
Primary Topic
Reproductive Biology and Fertility
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Effect of growth hormone on euploid blastocyst rate in advanced-age women: a prospective, randomized, controlled trial

Change Hu, Fei Gong, Lin Ge, Niu Qin et al.
Scientific Reports
Reproductive Biology and Fertility
article

Effect of growth hormone on euploid blastocyst rate in advanced-age women: a prospective, randomized, controlled trial

Change Hu, Fei Gong, Lin Ge, Niu Qin, Shunji Zhang, Yangqin Peng, Tang Yi, Zong Yurong, Liu Liqing, Guan Ruyi, Yang Xiaoyi
article en

Abstract

Older women exhibit an increased incidence of chromosomal abnormalities in preimplantation embryos. At present, it remains uncertain whether growth hormone (GH) administration can improve embryonic ploidy status in this population.This study aimed to investigate whether GH administration can improve the euploid blastocyst rate in older women undergoing preimplantation genetic testing for aneuploidy (PGT-A). This is a prospective, randomized, controlled trial.We included 316 advanced-age infertile women (≥ 35 years) undergoing PGT-A.Participants in the GH group received subcutaneous GH injection at a dose of 2 IU/day starting from the mid-luteal phase of the two menstrual cycles preceding the initiation of ovarian stimulation. Between the initiation of ovarian stimulation and the day of human chorionic gonadotropin (HCG) trigger, GH was administered at an increased dose of 4 IU/day.The control group did not receive additional interventions. The primary endpoint was the euploid blastocyst rate which was calculated as follows: number of euploid blastocysts/total number of blastocysts × 100%. The number of euploid blastocysts per patient was 0.98 ± 0.99 in the GH group and 0.89 ± 0.99 in the control group ( P = 0.534; absolute difference [95% CI]: 0.00 [− 0.00, 0.00]). Further, there was no significant difference in the euploid blastocyst rate between the GH group (37.78% ± 36.77%) and the control group (31.55% ± 33.99%; P = 0.325; absolute difference [95% CI]: 0.01% [-0.00%, 16.67%]). Our findings indicated that GH supplementation did not significantly improve the euploid blastocyst rate in advanced-age women undergoing PGT-A. These findings suggest that routine GH co-treatment may not increase the euploid rate in this population. Trial registration: ChiCTR2100052433; http://www.chictr.org.cn , Oct 26, 2021.

Scientific Reports
Central South University (CN), Reproductive & Genetic Hospital CITIC-Xiangya (CN)
Reproductive Biology and Fertility
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon